ライフサイエンスコーパス: injection site

1 Nef as clade B consensus sequences (separate injection sites).

2 avoidable) subcutaneous phototoxicity at the injection site.

3 e release of a biopharmaceutical from the SC injection site.

4 ) lymph node (LN) and the distal LN from the injection site.

5 nly subjective symptom was local pain at the injection site.

6 initiates inflammatory events locally at the injection site.

7 igration of contrast agents from the initial injection site.

8 on of mild subconjunctival hemorrhage at the injection site.

9 s and nausea, and ulceration and pain at the injection site.

10 ced more rapid neutrophil recruitment to the injection site.

11 iunit best frequency was determined for each injection site.

12 phage, and dendritic cell recruitment to the injection site.

13 t and the antigen both being retained at the injection site.

14 ferred by the neural population local to the injection site.

15 forced by decapitating the plants above the injection site.

16 ns were observed in brain areas far from the injection site.

17 experiences, most commonly irritation at the injection site.

18 olive established the zonal identity of the injection site.

19 te transendothelial migration at the vaccine injection site.

20 crease of Iba1-positive microglia around the injection site.

21 s, and (much less frequently) itching at the injection site.

22 side of the spinal cord contralateral to the injection site.

23 IL-33 s.c. and monitored its effects at the injection site.

24 ntry, via synapses in close proximity to the injection site.

25 as arginase-1, IDO1, PDL1, and IL-10 at the injection site.

26 ainful and the effects are restricted to the injection site.

27 fection from the initial peripheral mosquito injection site.

28 al residue or adverse tissue reaction at the injection site.

29 ut also long-term antigen persistence at the injection site.

30 re probably related to remnants of tracer at injection sites.

31 lling in each eye, representing a total of 6 injection sites.

32 -validated model estimated on only the other injection sites.

33 their actual location with that predicted by injection sites.

34 a function of distance between the cortical injection sites.

35 mbers of neurons projecting to two different injection sites.

36 y erythematous and vesiculous plaques at the injection sites.

37 s, but formed patches at distances away from injection sites.

38 ne the origin of multisynaptic inputs to the injection sites.

39 nt to human myeloid sarcomas, emerged at the injection site 30-50 days after cell implantation and co

40 ed after epicardial application of FG at the injection site (37.5 +/- 8.2%).

41 Near the injection site, a significant portion of alphaS inclusio

42 (13/62) of placebo recipients reported >/=1 injection-site adverse events (AEs), and 52% (149/289) a

43 difference primarily due to higher rates of injection-site AEs and headache.

44 articipants who received ID vaccine had mild injection-site AEs compared with participants who receiv

45 Solicited AEs included injection-site AEs from days 1 to 5, and joint pain, joi

46 on could influence liposome retention at the injection site after 4 days, whilst higher levels (25mol

47 e chorioretinal atrophy was developed at the injection site after a single, standard low-dose intravi

48 Different injection sites also result in differences in laterality

49 vector genomes being restricted to the brain injection site and an absence of overt toxicities.

50 Notably, removal of the injection site and associated alum depot, as early as 2

51 ctivity and potential toxicities both at the injection site and beyond.

52 curred rapidly and transiently at the muscle injection site and draining lymph node postinjection, co

53 coll was also preferentially retained at the injection site and draining lymph nodes and produced few

54 induction of innate immune responses at the injection site and draining lymph nodes.

55 nflammatory reaction limited to subcutaneous injection site and elicited no other toxic effects.

56 ins (NF2, NF3, and NF4) were confined to the injection site and eventually cleared.

57 ents were transient grade 1 to 2 pain at the injection site and flu-like symptoms following IDI, some

58 ons of the B. burgdorferi populations at the injection site and in distal tissues determined.

59 peridone reported more adverse events at the injection site and more extrapyramidal symptoms.

60 preferred for the particles to remain at the injection site and slowly release drugs that may then di

61 adverse events within 28 days, and solicited injection site and systemic reactogenicity on the day of

62 ased physiological buffer that mimics the SC injection site and the infinite sink of the body.

63 djuvants were retained preferentially at the injection site and the nearest draining lymph nodes comp

64 The retention of the vehicles at the injection site and the release rate were determined pred

65 muscle layer under the perianal skin at the injection site and then diffused out over time.

66 rtment simulates the drug migration from the injection site and uptake by the blood and/or lymph capi

67 up 2, one rabbit developed an abscess at the injection site and was sacrificed at 1 week.

68 Radioactivity at the T cell injection sites and in the thigh (background) was measur

69 system (CNS) pathways to regions far beyond injection sites and reduced survival with a highly repro

70 The locations of injection sites and resulting labeled neurons were furth

71 ation, and it was associated with more local injection-site and extrapyramidal adverse effects.

72 ally well-tolerated, with increased rates of injection-site and systemic AEs compared to placebo, and

73 ary endpoints were frequency and severity of injection-site and systemic reactions within 28 days of

74 Solicited reports of injection-site and systemic reactions within 7 days afte

75 =40 [60%]) or tenderness (n=32 [47%]) at the injection site, and the most frequent systemic reactogen

76 s as a function of distance between cortical injection sites, and found that there was a highly regul

77 to PsACWY (1996 subjects), tenderness at the injection site appeared to be more frequent in the PsA-T

78 The transfected brain cells near the injection site appeared to be mostly microglial.

79 t the two tracers behave very similarly when injection sites are well matched.

80 e distribution of the labeled plasmid at the injection site at various time points (from hours to day

81 cells could not be promptly recruited to the injection site before the injected cGAMP was diffused ou

82 e specifically targeted to cells local to an injection site, brightly labelling axons even when coexp

83 ultiple locations that were distant from the injection site but within the confines of the bleb creat

84 M-MDSCs infiltrated the vaccine injection site, but not vaccine-draining lymph nodes.

85 myelinating lesions were not centered on the injection site, but rather formed 1 week later at the wh

86 recruitment of multiple immune cells at the injection site, but their cellularity and phenotypes wer

87 luorescent dyes label axon terminals near an injection site, but unfortunately, also that of nearby f

88 neurons were densely distributed around the injection sites, but formed patches at distances away fr

89 g of these cases reveals that the centers of injection sites can be reconstructed, on average, to wit

90 We investigated how the injection site chosen for vaccination dictates CD8 T cel

91 mes did not improve antigen retention at the injection site compared surface adsorbed antigen.

92 ded engraftment of transplanted cells at the injection site compared with a standard injection techni

93 beled cells in the immediate vicinity of the injection site, compared to 10% in AII.

94 he new shoot apex that differentiated at the injection site contained bar(au)-free plastids in 30-40%

95 howed that the projection zone of a cortical injection site could be predicted with considerable accu

96 lution) was performed in 9 eyes, followed by injection site cryotherapy.

97 l, the hypointense areas on MR images at the injection sites decreased over time.

98 After 1 month, the retina around the injection site demonstrated diffuse retinal pigment epit

99 ed in vaccines for antigen stabilization and injection site deposition.

100 endent on the presence of the tumor, because injection site did not appreciably affect CD8 T cell pri

101 concomitant triple-freeze cryotherapy at the injection site during needle withdrawal for prevention o

102 l back, mechanical stimulation 7 mm from the injection site elicited discrete hindlimb scratch bouts

103 eaction in 445 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 2

104 Alopecia, injection site erythema, and pruritus were 13%, 27%, and

105 o, the most common adverse events were again injection-site erythema (33 [8%] of 416 with 50 mg siruk

106 upper respiratory tract infection (8%), and injection-site erythema (6%).

107 st common adverse events in this period were injection-site erythema (four [1%] with placebo, 22 [8%]

108 ifferences between administration routes for injection-site erythema (n=10 [12%] and n=0, respectivel

109 possibly related to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolyti

110 Injection-site erythema was the most commonly coded term

111 rogenitors migrated up to 1,500 mum from the injection site, expressed genes and proteins characteris

112 f transgene expression beyond the subretinal injection site following subretinally delivered AAV vect

113 nd VEEV at 12 h postinoculation (hpi) at the injection site (footpad) and as early as 72 hpi in the b

114 counterintuitive relationship whereby total injection site footprint and thus distribution cost decl

115 extend both rostrally and caudally from the injection site for as much as three-fourths of the longi

116 remain viable but permanently dormant at the injection site for nearly a year, whereas the expression

117 ith PEG-PLLA copolymer were preserved at the injection site for weeks and months indicating extremely

118 cue of the retinal structure adjacent to the injection site, global functional rescue of the entire r

119 set of spinal or paraspinal infection at the injection site has been increasingly reported and is occ

120 ), dizziness (2%), nasopharyngitis (1%), and injection site hematoma (1%).

121 Only 1 adverse event (mild injection site hematoma) was assessed as treatment-relat

122 ibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively.

123 Epicardial pacing of the injection site identified matching beats arising from th

124 ted on the following topics: spacing between injection sites (ie, vaccine spacing), site of injection

125 5/tCO2) was 190x larger than for the farther injection site, illustrating how careful siting would mi

126 With the exception of minor bleeding at the injection site in a few animals injected either by jet i

127 ulted in Ca(2+)-driven PVCs arising from the injection site in all hearts studied.

128 of the cells were ipsilateral to Fluoro-Gold injection sites in both the RVLM and CVLM, and the remai

129 als were also observed contralateral to mPFC injection sites in rats, appearing as a less dense "mirr

130 The injection sites included representations ranging from th

131 ed infiltration of inflammatory cells at the injection site, indicating a potential pathophysiologica

132 The most common adverse effects were injection site induration and tenderness.

133 ines were avirulent in mice and induced less injection site inflammation than recombinant PA adsorbed

134 also activate Mrgprb2 and MRGPRX2, and that injection-site inflammation is absent in mutant mice.

135 Patient age and weight, new injection site location, addition of topotecan, concomit

136 The injection site locations ranged from 2 degrees to 10 deg

137 lution, and the thrombus was either near the injection site (M1) or flushed into the superior divisio

138 icardially into predetermined areas and each injection site marked.

139 Pain at the injection site, mostly grade 1 and grade 2, was the most

140 steeply with rostrocaudal distance from the injection sites, much more so than following perirhinal

141 5% of patients in any group) were diarrhoea, injection-site nodules, nausea, and urinary tract infect

142 ries of patients with local reactions at the injection sites of meglumine antimoniate in whom type IV

143 rom countries over acceptability of multiple injections, sites of administration, and safety.

144 fects consisted mostly of mild and transient injection site or flu-like symptoms.

145 no evidence of VGX-6150 accumulation at the injection site or in any organ 1 month following the 14(

146 Severe injection site or systemic events were uncommon.

147 These abnormalities were found at the injection site or within the meridian of the injection a

148 l water quality, either from those deep HVHF injection sites or from the surface or shallow subsurfac

149 salt aluminum hydroxide (alum) at the muscle injection site over multiple timepoints.

150 issue damage was observed at the collagenase injection site over time, and was associated with locali

151 dest amounts of new bone formation in closed injection sites over a periosteal surface.

152 Vaccinees reported injection site pain (52% vs 17%) and erythema (73% vs 25

153 adverse event rates were similar except for injection site pain (dose 1: 65.4% QIV, 54.6% TIV-Vic, 5

154 Headache (in clinical trials) and injection site pain (postapproval) were the most commonl

155 Injection site pain occurred more frequently with adjuva

156 nic side effects such as fever, myalgia, and injection site pain that have reduced their acceptance i

157 Injection site pain was the most common adverse event, r

158 Fatigue, myalgia, headache, and injection site pain were the most common solicited react

159 ly with LY2951742 than with placebo included injection site pain, erythema, or both (21 [20%] of 107

160 Injection site pain, itching, and erythema (mostly mild)

161 IL Sb adverse events were limited to injection site pain, with a mean value of 1.0 (mild).

162 Local reactions were mainly injection site pain/tenderness, with no reported fever o

163 group (n=10 [48%]; p=0.0049), mostly due to injection-site pain (n=55 [59%]).

164 The most common adverse events were mild injection-site pain and pruritus.

165 ) of 27 Malians boosted with MVA-BN-Filo had injection-site pain or tenderness.

166 discontinuation (two [<1%] of 230 patients); injection-site pain was reported most frequently.

167 Injection-site pain was significantly more frequent amon

168 during treatment were attacks of angioedema, injection-site pain, and headache.

169 The most common adverse events were injection-site pain, fatigue, myalgia, and headache.

170 The most frequent adverse events were injection-site pain, upper respiratory tract infection,

171 ed and cut parallel to the surface to reveal injection sites, patterns of labeled cells, and patterns

172 Irrespective of the injection site (perirhinal or temporal neocortex) and ta

173 lso induced in brain regions distal from the injection site, predominantly in neurons.

174 The dye content of the injection sites ranged from 371 to 1,441 pmol, which rep

175 Detailed clinical (including injection site reaction (ISR) grading), plasma pharmacok

176 uently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followe

177 thma, upper respiratory tract infection, and injection site reaction.

178 The most common adverse event was injection site reaction.

179 among patients who received bococizumab was injection-site reaction (12.7 per 100 person-years).

180 The most common adverse event was injection-site reaction with one patient in the group of

181 t common adverse events in the GA group were injection site reactions (35.5% with GA vs 5.0% with pla

182 b vs 13 [6%] patients receiving placebo) and injection site reactions (60 [16%] vs eight [4%]) occurr

183 Patients in the anakinra group had more injection site reactions (68% [17 of 25] vs. 4% [1 of 25

184 lacebo group vs 47% in the dupilumab group), injection site reactions (7% vs 40%, respectively), and

185 Common adverse events included injection site reactions (78% with mipomersen, 31% with

186 SC injection site reactions (mostly mild) occurred in 19 SC

187 lecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7).

188 Injection site reactions after Tdap immunization were re

189 .4%] and 378 [9.5%; 95% CI, 8.6%-10.5%] with injection site reactions and 66 [1.7%; 95% CI, 1.3%-2.1%

190 Injection site reactions and gastrointestinal symptoms w

191 Adverse events included injection site reactions and influenza-like symptoms.

192 ving biologic agents, most frequently citing injection site reactions and lack of efficacy as reasons

193 Injection site reactions and transient elevations of liv

194 n the occurrence of significantly more local injection site reactions in patients treated with SC ada

195 ich was mainly because of a higher number of injection site reactions in the anakinra group.

196 Injection site reactions occurred in 20 of 106 patients

197 Injection site reactions occurred in 3.8% of patients re

198 Adverse events were mostly injection site reactions occurring after QbG10 administr

199 requently reported adverse events were local injection site reactions such as injection site swelling

200 associated with a higher frequency of local injection site reactions than was the use of needle and

201 Rates of injection site reactions were low.

202 Injection site reactions were mild or moderate.

203 Systemic and injection site reactions were mild, transient, and simil

204 Mild injection site reactions were more common in the Cervari

205 Injection site reactions were more frequent in the intra

206 Injection site reactions were more frequent with rilonac

207 Injection site reactions were recorded in nine (9%) pati

208 Mild injection site reactions were the most common adverse ev

209 Injection site reactions were the most frequently report

210 y vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermal

211 were assessed by monitoring adverse events, injection site reactions, and laboratory test results.

212 s associated with peginterferon beta-1a were injection site reactions, influenza-like symptoms, pyrex

213 ith the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse eve

214 verity of reported adverse events, including injection site reactions, were similar in the generic dr

215 ommon treatment-emergent adverse events were injection site reactions.

216 Five patients reported transient injection site reactions.

217 s promising but invasive and associated with injection site reactions.

218 erixafor were gastrointestinal disorders and injection site reactions.

219 ociated adverse events were GI disorders and injection site reactions.

220 re mild or moderate, and 94% of patients had injection site reactions.

221 nemia, fatigue, thrombocytopenia, fever, and injection site reactions.

222 iratory tract infections (33-41% vs 35%) and injection-site reactions (13-26% vs 13%).

223 events in drisapersen-treated patients were injection-site reactions (14 patients given continuous d

224 with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4%

225 both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were t

226 nes than with placebo; these events included injection-site reactions (in 28.5% of the patients in th

227 eater median number of docetaxel cycles) and injection-site reactions (P<.001).

228 tidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPR

229 Injection-site reactions and conjunctivitis were more co

230 most frequently reported adverse events were injection-site reactions and dizziness, which were self-

231 rticipants in the albiglutide group had more injection-site reactions and fewer gastrointestinal even

232 We noted grade 1-2 injection-site reactions in 36 (33%) of 110 patients in

233 Few injection-site reactions occurred (3%).

234 Injection-site reactions occurred in 5% of the patients

235 Injection-site reactions occurred in more patients given

236 Injection-site reactions occurred in most patients, but

237 Injection-site reactions to the drug were common.

238 Injection-site reactions were mild (3648 [84%] of 4360 i

239 Injection-site reactions were more common in the bocociz

240 versus control, except for a higher rate of injection-site reactions with alirocumab.

241 Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse event

242 ubcutaneous group (mainly grade 1 or 2 local injection-site reactions).

243 igh incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was w

244 Injection-site reactions, nasopharyngitis, nausea, and h

245 eurocognitive events), with the exception of injection-site reactions, which were more common with ev

246 A85A was associated with expected mild local injection-site reactions.

247 ents (AEs) experienced by subjects were mild injection-site reactions.

248 The most common adverse events were mild injection-site reactions.

249 ons with IONIS-APO(a)Rx were associated with injection-site reactions.

250 IONIS-APO(a)-LRx was associated with no injection-site reactions.

251 most common adverse event in all groups was injection-site redness (up to 25% of participants).

252 ofiles of inflammatory skin reactions at the injection sites reflected an IFN-alpha-signature, wherea

253 of polyplexes with APCs was observed at the injection site regardless of polymer structure, whereas

254 proved survival approximately 38-fold at the injection site relative to injected isolated cells, and

255 Simultaneous injection of OTAB at a s.c. injection site remote from the sciatic nerve did not res

256 Examination of the injection site revealed numerous monocytes and relativel

257 A region within 5-15 nm of the injection site shows a marked reduction in manipulation.

258 n vitro system, termed Scissor (Subcutaneous Injection Site Simulator).

259 By assaying Il1b transcripts in the injection site skin of CFA-immunized mice, we found that

260 se events (all grades) consisted of local DC injection site skin reactions (100%), transient post-DC

261 FI was of value for identification of near-injection-site SNs (two patients), SNs located in comple

262 these connections depend on the location of injection sites, so that lateral PE receives preferentia

263 ISFIs may be, in part, due to differences in injection site stiffness.

264 confirm that implant behavior is affected by injection site stiffness.

265 BMSCs that migrated from the injection site survived at the border of DRGs for more t

266 were local injection site reactions such as injection site swellings (Group 1: 30% of patients, Grou

267 nd was associated with more reactions at the injection site than the hepatitis A virus vaccine and sa

268 mature ventricular complexes (PVCs) from the injection site that were dose-dependent (low-dose [30-60

269 fish larvae are infected via the two primary injection sites, the hindbrain ventricle and caudal vein

270 LPS egress from a s.c. injection site thus occurred during many weeks and was m

271 Gene expression profiling in injection-site tissues from mice immunized with SAM-base

272 A 1.2 muL solution plug was pumped from an injection site to a detector without the need for a chan

273 in the propagation of tau pathology from the injection site to neuroanatomically connected brain regi

274 trasound, the contrast agent flowed from the injection site to the opposite ventral anterior SCS and

275 and the spreading of tau inclusions from the injection sites to anatomically connected brain regions.

276 going clinical trials have used a variety of injection sites, vaccination site is potentially a criti

277 ocytose and process Ag, and migrate from the injection site, via the afferent lymphatic vessels, into

278 ted a faster clearance of (18)F-FLT from the injection site vs. (18)F-FDG (p </= 0.001), indicating l

279 Pain at the injection site was more common in women given quadrivale

280 Pain at the injection site was the most common adverse event.

281 In both studies, pain and tenderness at the injection site was the most frequent local symptoms (37

282 T cells; (124)I-iodide uptake at the T cell injection site was time-dependent and associated with hi

283 d by aluminum hydroxide nanoparticles in the injection sites was milder than that induced by micropar

284 of regions of interest, and the location of injection sites was reconstructed relative to cytoarchit

285 Pain at the injection-site was the most common local reaction.

286 hree mosaics each (each region at a separate injection site) was compared to a whole-protein vaccine

287 Adverse events related to injection site were more common in the 9vHPV group than

288 kidneys, spleen, and hind paw containing the injection site were removed and weighed; and activity in

289 he lateral lemniscus in isolation, and these injection sites were correlated with monaural responses.

290 jacent to or rostrocaudally distant from the injection sites were performed.

291 ields of CTB-Au-labeled cells in V1 opposite injection sites were plotted in layers 2/3 or 4B.

292 Microstimulation and tracer injection sites were verified histologically to be locat

293 matory skin reactions at pegylated IFN-alpha injection sites, were analyzed for the expression of rel

294 jecting DA neurons was evident in the vector injection site, whereas DA neurons outside this site wer

295 n the lymphatic vessels that connect an i.m. injection site with the local lymph node has not been in

296 Sealing injection sites with FG or lowering ventricular rate by

297 etration into the cerebrospinal fluid at the injection site, with transport through cerebrospinal flu

298 stabilized nanodroplets disappeared from the injection site within 48h.

299 Injection sites within S1 were matched so that direct co

300 s properties of CTB allow small and discreet injection sites yet still show robust retrograde labelin